Enrollment has closed with 474 subjects enrolled!


Results expected in early 2026

About Us

We are a team of researchers at Oregon Health and Science University and 20+ partner sites across the United States and Canada conducting a Patient-Centered Research Outcomes Institute (PCORI)-funded pragmatic trial to determine whether 2-drug therapy is as effective as and more tolerable than 3-drug therapy for MAC pulmonary disease, or “MAC2v3”.

Clinicaltrials.gov Information Page with eligibility criteria: https://clinicaltrials.gov/ct2/show/NCT03672630

Interested in the results of the study?

Primary data collection for this study will be complete by November 2025 with the first results being posted on clinicaltrials.gov in 2026. Any publications will be linked through the clinicaltrials.gov page linked above. We will also be posting patient-friendly updates on community web pages of our patient advocacy partners, COPD Foundation and NTM Info & Research. If you have questions or wish to be notified when results are released, please reach out through the email below.

Thank you to the MAC2v3 enrolling sites!

---